Serotonin syndrome

Adverse Drug Reaction Bulletin

Volumn , Issue 243, 2007, Pages 931-934

  Thanacoody, Ruben H K ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CHLORPHENIRAMINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; ILLICIT DRUG; LINEZOLID; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OPIATE; OXYCODONE; PAROXETINE; PETHIDINE; SELEGILINE; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TRAZODONE; TRYPTOPHAN; UNINDEXED DRUG; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; BACTERIAL INFECTION; CLINICAL FEATURE; COOLING; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABUSE; DRUG FATALITY; DRUG MECHANISM; DRUG OVERDOSE; FEEDBACK SYSTEM; HUMAN; HYPERPYREXIA; HYPERTHERMIA; MIGRAINE; NERVE STIMULATION; OBESITY; PRESCRIPTION; REVIEW; SEROTONIN METABOLISM; SEROTONIN RELEASE; SEROTONIN SYNDROME; SEROTONINERGIC NERVE; SYNAPSE; TOBACCO DEPENDENCE;

EID: 35349019220     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fad.0000292087.11074.2f     Document Type: Review

References (47)

1. Gillman PK. Serotonin syndrome: history and risk. Fundamental Clinical Pharmacology 1998;12:482-491.
2. Boyer EW, Shannon M. Current concepts: the serotonin syndrome. New England Journal of Medicine 2005;352:1112-1120.
3. Asch DA, Parker RM. The Libby Zion case. New England Journal of Medicine 1988;318:771-775.
4. Sternbach H. The serotonin syndrome. American Journal of Psychiatry 1991;148:705-713.
5. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Quarterly Journal of Medicine 2003; 96:635-642.
6. Hegerl U, Bottlender R, Gallinat J, et al. The serotonin syndrome scale: first results on validity. European Archives of Psychiatry & Clinical Neuroscience 1998;248:96-103.
7. Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960;10:1076-1078.
8. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biological Psychiatry 2006;59: 1046-1051.
9. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology 2007;151:737-748.
10. AmstKKerdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depression & Anxiety 1997;5:84-90.
11. Ferrer-Dufol A, Perez-Aradros C, Murillo EC, Marques-Alamo JM. Fatal serotonin syndrome caused by moclobemide-clomipramine overdose. Journal of Toxicology & Clinical Toxicology 1998;36:31-32.
12. Francois B, Marquet P, Desachy A, et al. Serotonin syndrome due to an overdose of moclobemide and clomipramine. A potentially life-threatening association. Intensive Care Medicine 1997;23:122-124.
13. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone. Psychosomatics 1992; 33:235-236.
14. McCue RE, Joseph M. Venlafaxine and trazodone-induced serotonin syndrome. American Journal of Psychiatry 2001;158:2088-2089.
15. Nisijima K, Shimizu M, Abe T, Ishiguro T. A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. International Clinical Psychopharmacology 1996;11:289-290.
16. Reeves RR, Bullen JA. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 1995;36:159-160.
17. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Journal of Toxicology & Clinical Toxicology 2004;42:277-285.
18. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Quarterly Journal of Medicine 2003;96:369-374.
19. Isbister GK, Hackett LP, Dawson AH, et al. Moclobemide poisoning: Toxicokinetics and occurrence of serotonin toxicity. British Journal of Clinical Pharmacology 2003;56:441-450.
20. Hawley CJ, Quick SJ, Ratnam S, et al. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. International Clinical Psychopharmacology 1996;11:187-191.
21. Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clinical Toxicology 2007;45: 45-50.
22. Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Human Psychopharmacology 2006;21:117-125.
23. Sobanski T, Bagli M, Laux G, Rao ML. Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry 1997;30:106-107.
24. Bertschy G, Ragama-Pardos E, Ait-Ameur A, et al. Lithium augmentation in venlafaxine non-responders: an open study. European Psychiatry 2003;18:314-317.
25. Adan-Manes J, Novalbos J, Lopez-Rodriguez R, et al. Lithium and venlafaxine interaction: a case of serotonin syndrome. Journal of Clinical Pharmacology & Therapeutics 2006;31:397-400.
26. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. Clinical Neuropharmacology 2004;27:219-222.
27. Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Annals of Internal Medicine 1955;42: 417-424.
28. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clinical Infectious Diseases 2006;42:1578-1583.
29. Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006;26:1784-1793.
30. Navarro A, Perry C, Bobo WV. A case of serotonin syndrome precipitated by abuse of the anticough remedy dextromethorphan in a bipolar patient treated with fluoxetine and lithium. General Hospital Psychiatry 2006;28:78-80.
31. Skop BP, Finkelstein JA, Mareth TR, et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. American Journal of Emergency Medicine 1994;12:642-644.
32. Roy S, Fortier LP. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafaxine. Canadian Journal of Anaesthesia 2003;50:32-35.
33. Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. Annals of Pharmacotherapy 2006;40:155-157.
34. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Annals of Clinical Psychiatry 1997;9:7-13.
35. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort. Journal of Psychopharmacology 2002;16:401.
36. Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Annals of Pharmacotherapy 2000;34:871-874.
37. Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. International Clinical Psychopharmacology 1997;12:61-63.
38. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Annals of Pharmacotherapy 1998;32:33-38.
39. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996;16:323-327.
40. Alisky JM. Can chlorpheniramine cause serotonin syndrome? Singapore Medical Journal 2006;47:1014.
41. Serotonin syndrome. Canadian Adverse Reaction Newsletter 2003; 13:3-4. http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carnbcei_v13n3_e.html.
42. Vuori E, Henry JA, Ojanpera I, et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003;98:365-368.
43. Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. Journal of Clinical Psychiatry 2004;65:1520-1524.
44. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort. Journal of Psychopharmacology 2002;16:401.
45. Mathew S, Linhartova L, Raghuraman G. Hyperpyrexia and prolonged postoperative disorientation following methylene blue infusion during parathyroidectomy. Anaesthesia 2006; 61:580-583.
46. Majithia A, Stearns MP. Methylene blue toxicity following infusion to localize parathyroid adenoma. Journal of Laryngology and Otology 2006;120:138-140.
47. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology (in press).